Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1386 for Esophageal Sensitivity in GERD
NCT01019928Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of AZD-1386 in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Started Nov 2009; status: completed.
02
Drugs
AZD-1386
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01019928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019928.